Latest news with #AdamBrown
Otago Daily Times
04-08-2025
- Health
- Otago Daily Times
Pupils' art bringing cheer to cancer patients through Bags of Hope project
East Otago High School year 7 pupil Adam Brown and Carley Porter, both 12, display the bags they decorated for the Cancer Society. PHOTO: PETER MCINTOSH Local secondary school students hope their art projects put a smile on cancer patients' faces. Cancer Society Coastal Otago community manager Suz Russell said the Bags of Hope project was about giving children the opportunity to give messages of hope to cancer patients. The bags were given to patients at Dunedin Hospital's oncology department to store their clothes while they had scans or chemotherapy. It helped them remember people were thinking about them, Ms Russell said. About 1500 bags were made for the hospital each year. Students at East Otago High School made about 100 bags. Art teacher Rachel Foster said the project was about sending encouragement and positivity to those with cancer. She asked the students to use bright colours and inspirational messages. Ms Foster said the project was powerful because it gave students' work a meaning that they could be proud of. Her father-in-law had cancer and seeing the decorative bags in the oncology department cheered him up. "It was lovely to see that kind of connection." Year 7 pupil Carley Porter said her art was about staying positive and making every day count. One of the messages on her bags read "Believe in Miracles" because anything was possible. She wanted to be as inspiring and positive as possible in an effort to make someone battling with cancer smile. Carley's classmate Adam Brown made a painting with lots of balloons floating away. He said it was about letting go of your problems and letting them fly away like balloons. His message was to never give up and to enjoy everything.
Axios
04-08-2025
- Business
- Axios
More pharma giants embrace direct-to-consumer sales
Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients — and President Trump is pushing for more companies to get into the game. Why it matters: Direct-to-consumer sales require only a few mouse clicks, often without the need to manage appointments or insurance forms. Online sales can also bypass pharmacy middlemen, in theory lowering prices and providing more transparency into what patients have to pay. But there are tradeoffs, like the prospect of overprescribing or manufacturers steering patients toward expensive name-brand drugs. Driving the news: Trump on Thursday sent letters to the CEOs of 17 pharmaceutical companies, demanding they bring down U.S. prices within 60 days. The requirements include providing direct-to-consumer or direct-to-business drug purchasing models for certain products. Several pharma giants have already committed to these models or are exploring them, in part driven by the surging popularity of GLP-1 drugs that are expensive and often not covered by insurance. Eli Lilly last year became the first pharmaceutical company to launch a direct-to-consumer health care platform for its diabetes, obesity, migraine and select other medications. Pfizer and Novo Nordisk have since launched their own direct sales models, and the CEO of Roche said last month that the company is considering something similar for U.S. patients. In the first quarter of this year, about 25% of new prescriptions for Lilly's weight-loss drug Zepbound were fulfilled through LillyDirect, per a spokesperson. Consumer health companies like Hims & Hers have also helped popularize the concept among patients. How it works: Lilly's and Pfizer's DTC models start with virtual visits with independent practitioners working with telehealth platforms, who can — but are not obligated to — prescribe medicines in each company's program. Patients can then order medications directly from the company, and can often arrange to have them delivered to their homes. Some drugs on Lilly's DTC platform, including vials of Zepbound, are only available for patients who pay cash, which streamlines the process. Patients can use their commercial insurance for other drugs. Novo Nordisk's platform doesn't include the telehealth appointment but allows cash-paying patients who take GLP-1 drug Wegovy to have their prescription sent directly to the company. Patients can qualify for a lower price for the drug and home delivery. The other side: Direct-to-consumer models run the risk of pushing drugs on patients who may not need them, Adam Brown, a physician and health care strategist, wrote in a September op-ed in MedPage Today. Pharmacy benefit managers, who serve as intermediaries between health plans and the manufacturers, also want to temper enthusiasm for the new systems and claim they can save more. "PBMs want lower prices on every drug for every patient, and direct to consumer channels may provide one more way for some patients to gain access to some medications," Greg Lopes, vice president of public affairs and communications for the Pharmaceutical Care Management Association, said in an email. "In most cases however, patients will spend less out of pocket and face fewer safety concerns when their medications are delivered through their prescription drug benefits at their pharmacies and with their doctors involved." The intrigue: While Trump is pushing direct-to-consumer drug sales, Health Secretary Robert F. Kennedy Jr. has long been interested in limiting pharmaceutical companies' ability to advertise to consumers. Health and Human Services is "exploring ways to restore more rigorous oversight and improve the quality of information presented to American consumers who deserve nothing less than radical transparency," spokesperson Emily Hilliard told Axios.
Yahoo
03-08-2025
- Yahoo
How to look good on holiday as a man: the best trunks, linen shirts and sandals for summer 2025
High summer has arrived. Before you flick on the OOO and head to Heathrow, however, be sure you are fully prepared to pack a suitcase without finding yourself in one of life's more uncomfortable positions: sweating, swearing and staring at empty bags before an early flight. Rule one in preparation for holidays abroad: dig out any linens and slightly eccentric shirts that don't get a showing in the city and take them to a dry cleaner. This ensures a good part of your summer wardrobe will feel like new upon arrival — and avoids the nasty realisation that your white slacks still have grassy arse from the final night of summer 2024. Then, consider tactical purchases to facelift areas that need them. If your trunks are suncream stained, start there. Steer clear of the high street giants — the Zara shirts in Battersea Power Station are often the same as those at the Ibiza outpost, and it's excruciating to find yourself alongside a poly-blend twin at the beach bar — except for unidentifiable basics. Instead, head to the coterie of smaller London labels to look sophisticated abroad. 'To travel well is to dress with intention,' says Adam Brown, founder of Orlebar Brown, home to well-tailored swimmers. 'Dress for your destination with light, breezy linen, a splash of print, cuffs rolled up, flash a bit of ankle. The goal is not to blend in — it's to be remembered.' The trunks Let's start with the swimwear. A place to show a bit of flair. The market for posh men's swimmers is ever-growing — and each new label takes another bite out of Vilebrequin's lunch. The French swimwear label, now the uniform of rotund ex-bankers who moor themselves up to Côte d'Azur for weeks on end, needs an update on its turtle prints to stay in the race. Chicer is Orlebar Brown, which regularly produces elegant new designs (from night irises to a tempting collaboration with florist Burnt Fen Flowers). Not cheap, starting at £195, but elegant and recognisable for their nickel-effect fastening buckles. The newest player to enter the ring is Ram, founded by Marina Lambton, and set to launch next week. 'We have started the business with only six designs and we will gradually grow it,' says Marina of their drawstring, printed designs which retail at £150. Gusari, best known for its 'London' and 'Deia' tailored shorts style (from £125), and Abtany — which sells trunks and briefs with hand-painted brushstroke motifs from £140 — make up the rest of the cream of the crop. RAM Trunks, £150, Orlebar Brown Setter, £295, Gusari The Deia trunks, £125, The premium cottons Essential for the majority of locations and best done with a wink. SMR Days, the label which strives 'to provide an effortless wardrobe for men, made for laid-back days, home or away', is best known for its co-ords, often created using centuries-old Indian techniques. 'Lean into confident prints: holidays are the time to dial it up a bit. But don't combine prints unless you're a pro,' says co-founder Adam Shapiro. 'Wear fabrics that feel like vacation: light, natural materials like kala cotton or linen look like summer and help you beat the heat. No one wants polyester on the beach.' Their geometric block printed shirts (£195) can be paired with matching shorts or slacks. SMR Days Enamorados Organic Cotton Shirt in Blue Block Print, £245, Percival Percival Sorrento cotton linen trousers, £139, The shirts A good shirt is essential to model Oliver Cheshire, who founded his resortwear label CHÉ Studios with Toby Watkins in 2019. 'Natural fibre crochet tops in the daytime will keep you looking and feeling cool, while in the evening try something a little looser with a touch of shine like a silk shirt to really set the glamour tone,' he says. The short sleeve options start at £95 and go up to £200. Great linen shirts can be custom made at Blugiallo, or are perfectly serviceable from M&S, while Hackney-founded Percival has made a best seller of boxy, grandpa-style shirts. 'They are key for evenings when you need to look slightly more put-together but still want that untucked energy that says 'I'm on holiday and I'm having a brilliant time',' says founder Chris Gove. Percival Tessaro Knitted Stripe Polo, £129, CHÉ Studios Palma Cotton Applique Detail Polo, £140, Blugiallo White cotton linen shirt, £121, The key accessories Polish off with a good pair of sunglasses. While heavy hitting designer label swim shorts or silk shirts can look naff, good Tom Ford or Gucci shades add luxury to an otherwise laid-back outfit. By way of beach bag, the Drake's Bengal Jute Poresh tote should do the job without breaking the bank. For footwear, Xero's £45 barefoot sandals are a current favourite among the fashion set. 'Accessories are key. You can be in a simple shirt and casual shorts but a great sandal or a coral necklace gives a bit of personality,' says SMR Days' Shapiro. 'Conversely, if you're really pushing a look, go with a flip-flop — or better yet, bare feet.' Xero Genesis, £45, Massimo Dutti Massimo Dutti Leather sandals with toe divider, £99.95, Drake's Drake's Maison Bengal jute Poresh tote, £80,
Business Wire
29-07-2025
- Business
- Business Wire
Quansys Biosciences Launches Q-View™ Imager Plus: Delivering Reproducible, high-impact ELISA Data with Ease
LOGAN, Utah--(BUSINESS WIRE)--Quansys Biosciences, a leader in multiplex immunoassay technology, today announced the launch of the Q-View™ Imager Plus, a next-generation imaging device designed to deliver reproducible, high-resolution ELISA results with streamlined workflows. Paired with the newly upgraded Q-View™ Software, the platform combines advanced imaging hardware with powerful and user-friendly analysis tools built to help academic, biopharma, and clinical laboratories generate reliable, publication quality, and regulation-ready data with speed and confidence. The new Q-View Imager Plus, along with the updated Q-View Software, provide consistent, high-quality data, for use in academic, biopharma, and clinical laboratories. Share At the core of the Q-View™ Imager Plus is a 35-megapixel multi-camera system with temperature-controlled sensors, offering high resolution images and consistent data quality across every plate. This design ensures reliable performance for both research and regulated laboratory environments, making it one of the most advanced imaging solutions in its class. 'We designed the Q-View™ Imager Plus and its upgraded Q-View™ Software to provide labs with consistent, high-quality data,' said Adam Brown, CEO at Quansys Biosciences. 'By combining advanced imaging with power and intuitive analysis tools, we have been able to deliver on our commitment to empower labs with tools that simplify complex workflows and deliver high-impact results, faster.' While most plate readers merely scan data points, the Q-View™ Imager Plus captures crystal-clear photographic images of 96-well plates and processes them in real time, allowing scientists to extract more meaningful results with less variability. The improved system extracts richer data with confidence, with active cooling ensuring consistent data from one image to the next, which is an essential requirement for clinical and regulatory settings. Key features include: Pre-focused optics for plug-and-play performance Integrated barcode scanning for automatic plate identification and reduced user error Internal qualification lighting for precise calibration without the need for external powered devices Durable and compact design, ideal for crowded lab environments Energy-saving mode to minimize wear, energy use, and noise when idle Compatible with automation and liquid handlers for high-throughput labs Field-upgradable firmware ensures longevity and adaptability 'Our goal with the Q-View Imager Plus was to give scientists a tool that combines high-quality imaging with practical usability,' said Dr. Kyle Berg PhD, who leads the R&D team at Quansys Biosciences. 'Every feature, from the pre-focuses optics to the integrated software, was engineered to reduce variability and make multiplex ELISA workflows faster and more reliable.' Availability The Q-View™ Imager Plus is now available for purchase worldwide. To request pricing or more information, visit or contact sales@ About Quansys Biosciences Quansys Biosciences is a leading biotechnology company specializing in multiplex ELISA testing solutions and quantitative protein analysis for both research and clinical applications. Its Q-Plex™ product line, Q-View™ Software, and Q-View™ Imagers are trusted by scientists and clinicians around the world to study a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. By delivering tools that improve efficiency, accuracy, and insight, Quansys empowers laboratories to generate high-quality biomarker data with confidence.
Yahoo
20-06-2025
- Business
- Yahoo
Integrated Theranostics Solutions and Bridge Oncology Launch Turnkey Theranostics Program to Help Fast-Track Radioligand Therapy Adoption
Strategic partnership brings Nuclear Medicine and Oncology together to advance the future of Theranostics PADUCAH, Ky., June 20, 2025 /PRNewswire/ -- Integrated Theranostics Solutions (ITS) and Bridge Oncology today announced a strategic partnership that brings together two leading consulting service providers to offer the market's only full-service, end-to-end solution for building and scaling theranostics programs. This exclusive collaboration equips private oncology clinics, independent urology practices, academic health systems, and regional networks, looking to enter theranostics, with the operational, clinical, and financial tools needed in one of medicine's fastest growing fields. Healthcare providers used to face months of delays trying to assemble expertise across multiple facets like regulatory compliance protocols, imaging infrastructure, revenue cycle operations and staffing models for theranostics. Many gave up before seeing patient results. "Today, organizations can launch a complete theranostics program with a single partner — from site readiness and clinical workflows to billing optimization and multi-site scaling — without juggling multiple vendors or long timelines," explained Adam Brown, founder of ITS. This comprehensive service offering brings together strong subject matter expertise in Nuclear Medicine, Theranostics, and Radiation Oncology to provide full program execution to help organizations effectively meet the demand to improve patient access to new diagnostic and therapeutic options. These services integrate eight key pillars, which include: Assessment and Strategic Planning Patient Care Coordination Regulatory Compliance Imaging and Equipment Integration Revenue Cycle Management Staffing Solutions Site Design and Readiness Training and Education "With the global Theranostics market projected to grow from $4.3 billion in 2024 to $12.7 billion by 2029,1- healthcare organizations are under increasing pressure to enter the space with confidence and speed," explained Jordan Johnson, CEO of Bridge Oncology. "The need for turnkey, low-risk program development for theranostics treatments has never been greater." "By joining forces, we can deliver a high-quality theranostics program in a financially sustainable way, streamlining reimbursement and cost recovery," Brown continued. "Although these types of programs can be complex, when they are executed well, they can support multi-site expansion, boost the institutional reputation, and support physician recruitment." While every engagement is tailored to a unique, organization-based strategy, the combined service line is intended to bridge the gap between innovation and implementation to accelerate program adoption and revenue generation, providing flexible solutions. "This marks the first time nuclear medicine and radiation oncology have come together to help make theranostics a practical reality," said Dr. Arpit Chhabra, a practicing radiation oncologist and partner in Bridge Oncology. "By integrating diagnostic imaging with targeted therapeutic intervention, we can achieve more accurate tumor characterization and deliver personalized treatment plans that elevate the standard of patient care. Ready to remove the roadblocks in your Theranostics journey? Book a call through our website and let's make it happen. 1Global Theranostics Market to Triple, Reaching $12.7 Billion by 2029." BCC Research, 26 Sept. 2024 For further information, please contact: Adam BrownIntegrated Theranostics SolutionsTime Zone: CST – Central time Tel: 770-715-9892Email: info@ About Integrated Theranostics Solutions Integrated Theranostics Solutions (ITS) is a consulting and management firm dedicated to advancing the field of theranostics. ITS bridges the gap between innovation and implementation, helping healthcare providers, researchers, and industry leaders navigate the complexities of theranostics with strategic insights and tailored solutions. From operational guidance to program development and everything in between, ITS supports the growth and integration of theranostics in clinical and research settings. About Bridge Oncology Bridge Oncology is a healthcare consulting and services company that supports all aspects of oncology care for clinical, financial, and operational excellence. With more than 20 years' experience supporting integrated cancer care practices and community oncology programs, Bridge Oncology is a trusted partner for organizations seeking to improve clinical workflow, create greater operational efficiency, and maximize financial performance. View original content to download multimedia: SOURCE Bridge Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
